3MDR as treatment for Posttraumatic Stress Disorder

Multi-modular Motion-assisted Memory Desensitization and Reconsolidation (3MDR) as treatment for Posttraumatic Stress Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22172

Enrollment

Registered

2015-06-19

Start date

2015-05-27

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic Stress Disorder Posttraumatische Stress Stoornis

Interventions

3MDR incorporates elements from Virtual Reality Exposure therapy (VREt) and Eye Movement Desensitization and Reprocessing (EMDR), while adding a motion-based component. In this combination, veterans a

Eligibility

Inclusion criteria

Inclusion criteria: - Between 18 and 70 years old. - Current chronic combat-related Posttraumatic Stress Disorder (Clinician Administered PTSD scale (CAPS) score > 50, for at least 3 months). - Being treatment resistant for trauma-focused psychotherapeutic interventions, which means having been treated for PTSD for a minimum of 6 consecutive months, of which 3 months with trauma-focused therapy, for instance Eye-Movement Desensitization Reprocessing (EMDR), Brief Eclectic Psychotherapy (BEP), Narrative Exposure Therapy (NET) or Prolonged Exposure (PE) with weekly sessions of at least 45 minutes or twoweekly session of at least 90 minutes. Or having started trauma-focused therapy at least twice and failing to engage in treatment.

Exclusion criteria

Exclusion criteria: - Acute suicidality - Difficulties walking, especially on a treadmill - Current severe alcohol and/or substance dependence according to DSM-IV (patients are allowed to enter after initial treatment of this disorder). - Acute psychosis. - Patients must be stable on their current psychotropic medication for a period of 4 weeks before entering the trial and agree to not make changes in dosages or add any new medications during the course of the 3MDR treatment.

Design outcomes

Primary

Measure	Time frame
PTSD symptom severity as measured with the Dutch version of the Clinician Administered PTSD Scale for DSM-5 (CAPS-5).	—

Secondary

Measure	Time frame
Secondary outcomes are self-reported PTSD symptoms (PCL-5), anxiety and depression symptoms (HADS), comorbid psychopathology (MINI), quality of life (Cantrill Ladder of Life), cognitive and behavioral avoidance (PABQ), interpersonal support (ISEL) and 3MDR experiences (3MDR-Q). Tertiary outcomes are neuropsychological functioning (verbal memory, visual memory, working memory and attention) and the stress response measured with cortisol in saliva and heart rate during sessions.	—

Measure

Time frame

Secondary outcomes are self-reported PTSD symptoms (PCL-5), anxiety and depression symptoms (HADS), comorbid psychopathology (MINI), quality of life (Cantrill Ladder of Life), cognitive and behavioral avoidance (PABQ), interpersonal support (ISEL) and 3MDR experiences (3MDR-Q). Tertiary outcomes are neuropsychological functioning (verbal memory, visual memory, working memory and attention) and the stress response measured with cortisol in saliva and heart rate during sessions.

—

Contacts

Public ContactMarieke van Gelderen

Rijnzichtweg 35

m.van.gelderen@centrum45.nl06-40391636

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)